I am a
Home I AM A Search Login

Papers of the Week

2022 Feb 17

Biomed Pharmacother


Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study.


Khorshiddoust R R, Khorshiddoust S R, Hosseinabadi T, Mottaghitalab F, Mokhtari F, Azadinia F, Mozdarani H, Shabani M, Emadi-Kouchak H, Taheri B, Khani-Juyabad F, Kashani M A, Sadoughi A, Zamanizadeh S, Maddah H, Aminzadeh M, Khanaki M, Saremi S, Rad A P, Fatehi A, et al.
Biomed Pharmacother. 2022 Feb 17; 149:112729.
PMID: 35276467.


The scientific researches on COVID-19 pandemic topics are headed to an explosion of scientific literature. Despite these global efforts, the efficient treatment of patients is an in-progress challenge. Based on a meta-study of published shreds of evidence about compounds and their botanic sources in the last six decades, a novel multiple-indication herbal compound (Saliravira®) has been developed. Based on the antiviral, anti-inflammatory, and immune-enhancing properties of its ingredients, we hypothesized that Saliravira® has the potential to act as an antiviral agent, accelerate treatment, and reduce undesirable effects of COVID-19.